These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7083208)

  • 1. In vivo effects of delta 1-testololactone on peripheral aromatization.
    Judd HL; Barone RM; Laufer LR; Gambone JC; Monfort SL; Lasley BL
    Cancer Res; 1982 Aug; 42(8 Suppl):3345s-3348s. PubMed ID: 7083208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen synthesis in human breast tumor and its inhibition by testololactone and bromoandrostenedione.
    Dao TL
    Cancer Res; 1982 Aug; 42(8 Suppl):3338s-3341s. PubMed ID: 7083197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of peripheral aromatization of androstenedione to estrone in postmenopausal women with breast cancer using delta 1-testololactone.
    Barone RM; Shamonki IM; Siiteri PK; Judd HL
    J Clin Endocrinol Metab; 1979 Nov; 49(5):672-6. PubMed ID: 489709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increases in serum estrogen levels during major illness are caused by increased peripheral aromatization.
    Spratt DI; Morton JR; Kramer RS; Mayo SW; Longcope C; Vary CP
    Am J Physiol Endocrinol Metab; 2006 Sep; 291(3):E631-8. PubMed ID: 16670151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of estrogen synthesis in human breast tumors by testololactone and bromoandrostenedione.
    Budnick RM; Dao TL
    Steroids; 1980 May; 35(5):533-41. PubMed ID: 7394858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor.
    Santen RJ; Santner SJ; Tilsen-Mallett N; Rosen HR; Samojlik E; Veldhuis JD
    Cancer Res; 1982 Aug; 42(8 Suppl):3353s-3359s. PubMed ID: 7083200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adrenal function under long-term raloxifene administration.
    Genazzani AR; Lombardi I; Borgioli G; di Bono I; Casarosa E; Gambacciani M; Palumbo M; Genazzani AD; Luisi M
    Gynecol Endocrinol; 2003 Apr; 17(2):159-68. PubMed ID: 12737677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of peripheral aromatization in postmenopausal women with breast cancer.
    Barone RM; Judd HL
    Surg Forum; 1978; 29():172-4. PubMed ID: 401126
    [No Abstract]   [Full Text] [Related]  

  • 9. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients.
    Dowsett M; Cunningham DC; Stein RC; Evans S; Dehennin L; Hedley A; Coombes RC
    Cancer Res; 1989 Mar; 49(5):1306-12. PubMed ID: 2917360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer.
    Reed MJ; Lai LC; Owen AM; Singh A; Coldham NG; Purohit A; Ghilchik MW; Shaikh NA; James VH
    Cancer Res; 1990 Jan; 50(1):193-6. PubMed ID: 2293555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steroid hormone profiles in women treated with aminoglutethimide for metastatic carcinoma of the breast.
    Samojlik E; Santen RJ; Kirschner MA; Ertel NH
    Cancer Res; 1982 Aug; 42(8 Suppl):3349s-3352s. PubMed ID: 7083199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels.
    Geisler J; Haynes B; Ekse D; Dowsett M; Lønning PE
    J Steroid Biochem Mol Biol; 2007 Apr; 104(1-2):27-34. PubMed ID: 17350249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.
    Lundgren S; Helle SI; Lonning PE
    Clin Cancer Res; 1996 Sep; 2(9):1515-21. PubMed ID: 9816328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.
    Dowsett M; Jones A; Johnston SR; Jacobs S; Trunet P; Smith IE
    Clin Cancer Res; 1995 Dec; 1(12):1511-5. PubMed ID: 9815951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of obesity to blood estrogens.
    Zumoff B
    Cancer Res; 1982 Aug; 42(8 Suppl):3289s-3294s. PubMed ID: 7083189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells.
    Shields-Botella J; Chetrite G; Meschi S; Pasqualini JR
    J Steroid Biochem Mol Biol; 2005 Jan; 93(1):1-13. PubMed ID: 15748827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of tamoxifen treatment on estrogen metabolism in postmenopausal women with advanced breast cancer.
    Levin J; Markham MJ; Greenwald ES; O'Connor JF; Zumoff B; Fukushima DK
    Anticancer Res; 1982; 2(6):377-80. PubMed ID: 7168557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen-estrogen production rates in postmenopausal women with breast cancer.
    Kirschner MA; Cohen FB; Ryan C
    Cancer Res; 1978 Nov; 38(11 Pt 2):4029-35. PubMed ID: 568029
    [No Abstract]   [Full Text] [Related]  

  • 19. Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways.
    Santen RJ; Leszczynski D; Tilson-Mallet N; Feil PD; Wright C; Manni A; Santner SJ
    Ann N Y Acad Sci; 1986; 464():126-37. PubMed ID: 3524346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route.
    Dowsett M; Goss PE; Powles TJ; Hutchinson G; Brodie AM; Jeffcoate SL; Coombes RC
    Cancer Res; 1987 Apr; 47(7):1957-61. PubMed ID: 3815384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.